



DRUG REGULATORY AUTHORITY OF PAKISTAN

PAKISTAN NATIONAL PHARMACOVIGILANCE CENTRE (PNPC)

LIST OF HIGH RISK MEDICINES/DRUGS

High risk drugs may cause significant patient harm or even death when used inappropriately. The consequences of errors or inappropriate use with the following drugs can be more devastating and of serious concern:

S. No	Class/Categories of Medication	Example of Medicines
1.	ADRENERGIC AGONIST	IV Form of Epinephrine, Phenylephrine, Norepinephrine etc.
2.	ADRENERGIC ANTAGONIST	IV form of Propranolol, Metoprolol, Labetalol
3.	ANESTHETIC AGENTS	General, Inhaled and IV form of drugs such as Propofol, Ketamine, Isoflurane, Sevoflurane, etc.
4.	ANTIARRHYTHMIC	IV form of Lidocaine, Amiodarone, etc.
5.	ANTITHROMBOTIC AGENT	Anticoagulants: Warfarin and low molecular weight Heparin, unfractionated Heparin Direct oral anticoagulant and factor Xa inhibitors: Rivaroxaban, Fondaparinux, etc. Thrombolytics: Reteplase
6.	CHEMOTHERAPEUTIC AGENTS	All parenteral and oral chemotherapeutic agents.
7.	EPIDURAL AND INTRATHECAL MEDICATION	Bupivacaine Ropivacaine
8.	INOTROPIC MEDICATIONS	IV form of Digoxin and Milrinone etc.
9.	INSULIN	All Insulins
10.	LIPOSOMAL FORMS OF DRUGS	Liposomal Amphotericin B and conventional counterpart amphotericin B desoxycholate
11.	MODERATE SEDATION AGENTS	IV form of Dexmedetomidine, Midazolam and Lorazepam etc.
12.	MODERATE AND MINIMAL SEDATION AGENTS FOR CHILDREN	Oral form of Chloral Hydrate, Midazolam and parenteral form of Ketamine etc.
13.	OPIOIDS	All opioids including Oral (liquid concentrate, immediate and sustained release formulation), Oral and transdermal forms.
14.	NEUROMUSCULAR BLOCKING AGENT	Succinylcholine, Rocuronium, Atracurium, Pancuronium, etc.
15.	HYPOGLYCEMICS, SULFONYLUREA	Oral form of Chlorpropamide, Glimepiride, Glyburide, Glipizide, Tolbutamide etc.
16.	ANTI-INFECTIVES	Amphotericin, Vancomycin, Aminoglycosides, Macrolides, Fluoroquinolones, and Carbapenems.
17.	OTHER	IV form of Oxytocin and Vasopressin, Potassium Chloride for injection concentrate and injections of Magnesium Sulphate, Potassium Phosphate and Promethazine.

Healthcare professionals are encouraged to actively monitor the safety of above mentioned high risk drugs and report any suspected adverse drug reaction either through downloadable paper based reporting form that can be assessed through:

<http://www.dra.gov.pk/docs/Suspected%20Adverse%20Reaction%20Reporting%20Form%20for%20Health%20Care%20Professionals.pdf> or online by visiting DRAP website.

Pakistan National Pharmacovigilance Centre (PNPC), Drug Regulatory Authority of Pakistan (DRAP)
Ministry of National Health Services Regulations & Coordination.

Address: 3rd Floor, Division of Pharmacy Services, DRAP Office, TF Complex, G-9/4, Islamabad

Email: npc@dra.gov.pk ; Website: www.dra.gov.pk ; Twitter: @DRA_Pakistan